| Ytd | -8.94% | |
| 1y | 189.19% |
| Open | 2.14 | Prev Close | 2.10 | Low | 2.14 | High | 2.15 | Mkt Cap | 371.46M |
| Vol | 0.00 | Avg Vol | 3.16M | EPS | -1.05 | P/E | -2.04 | Forward P/E | -0.19 |
| Beta | 1.33 | Short Ratio | 0.29 | Inst. Own | 3.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.94 | 200-d Avg | 1.93 | 1yr Est | 30.33 |
PALI News
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst cons
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug spec
Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock off
Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. C
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outpe
Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GL
Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative coli
Board strengthened with extensive biotechnology leadership, strategic transactions and capital marke
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioac
Management presentation to take place on Thursday, June 4 th at 3:45 PM ET Register for the webcast
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for tr
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE
Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have received a consensus rating of "M
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two we
I initiate Palisade Bio with a speculative buy, citing its differentiated microbiome-activated PDE4
Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have earned an average rating of "Mode
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or th
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of infl
On Thursday, 221 companies hit new 52-week lows.
On Monday, 85 stocks hit new 52-week lows.
On Monday, 61 companies hit new 52-week lows.
On Wednesday, 345 companies set new 52-week lows.
Tuesday's session saw 286 companies set new 52-week lows.
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced a
On Thursday, 175 stocks hit new 52-week lows.
On Tuesday, 298 companies achieved new lows for the year.
OnThursday, 137 stocks made new 52-week lows.
During Monday's session, 402 companies made new 52-week lows.
On Thursday, 930 stocks hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
On Tuesday, 507 stocks hit new 52-week lows.
On Monday, 429 stocks made new 52-week lows.
Gainers